Organism Attribute
Minimal Weight Reduction Observed with Low Doses of New Zealand’s GLP-1/GLP-2 Agonist
New Zealand, GLP-1/GLP-2 agonist, weight reduction, lowest doses, minimal effect.
AstraZeneca’s FASENRA Gains FDA Approval for Add-On Maintenance Treatment of Severe Asthma in Children Aged 6-11
AstraZeneca, FASENRA, Benralizumab, Severe Asthma, Pediatric Label Expansion, FDA Approval, Children Aged 6-11
Sarepta’s ELEVIDYS Gaining Ground Amidst Anticipation for Expanded Label Approval
ELEVIDYS, Age, Muscular Dystrophy, Duchenne, Sarepta, Labels (device), Child